Literature DB >> 1413896

Serum interleukin-6 in Kawasaki disease.

D S Kim1.   

Abstract

Kawasaki disease (KD) is an acute febrile illness of infancy and early childhood. In spite of extensive studies, the cause of KD is not known. Interleukin 6 (IL-6) has manyfold biological functions involved in the immune or inflammatory responses of the host to various stimuli. Here the author investigated whether IL-6 might be responsible for manifestations of KD, such as immunoglobulin hypersecretion, lymphocyte activation and systemic vasculitis. Serum IL-6 levels in KD were determined by ELISA. Usually sera from healthy children contained only negligible levels of IL-6. Serum IL-6 was markedly elevated in all patients with acute KD, which gradually decreased during the course of the disease. Serum IL-6 correlated with serum concentration of C-reactive protein and with serum soluble interleukin-2 receptor level, but did not show any correlation with peak platelet count during subacute phase of the disease. Increased serum IL-6 level did not show any relation to development of coronary aneurysms and dilatation. Further studies will be needed to examine the source and the pathogenetic roles of increased serum IL-6 in KD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1413896     DOI: 10.3349/ymj.1992.33.2.183

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  9 in total

1.  Kawasaki disease and hyponatremia.

Authors:  Jae Il Shin; Ji Hong Kim; Jae Seung Lee; Dong Soo Kim; Jae Young Choi; Jun Hui Sul
Journal:  Pediatr Nephrol       Date:  2006-08-08       Impact factor: 3.714

2.  Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.

Authors:  Akira Hachiya; Norimoto Kobayashi; Satoshi Matsuzaki; Yusuke Takeuchi; Yohei Akazawa; Tomonari Shigemura; Noriko Motoki; Junya Masumoto; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

3.  A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.

Authors:  Alolika Nandi; Priyankar Pal; Surupa Basu
Journal:  Rheumatol Int       Date:  2019-07-13       Impact factor: 2.631

4.  Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion in kawasaki disease.

Authors:  Goh-Woon Lim; Mina Lee; Hae Soon Kim; Young Mi Hong; Sejung Sohn
Journal:  Korean Circ J       Date:  2010-10-31       Impact factor: 3.243

Review 5.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

6.  Inhibition of IL-6 in the LCWE Mouse Model of Kawasaki Disease Inhibits Acute Phase Reactant Serum Amyloid A but Fails to Attenuate Vasculitis.

Authors:  Rebecca A Porritt; Carol Chase Huizar; Edward J Dick; Shyamesh Kumar; Renee Escalona; Angela C Gomez; Stefani Marek-Iannucci; Magali Noval Rivas; Jean Patterson; Thomas G Forsthuber; Moshe Arditi; Mark Gorelik
Journal:  Front Immunol       Date:  2021-04-09       Impact factor: 7.561

7.  Interleukin-6, vascular endothelial growth factor and transforming growth factor beta 1 in canine steroid responsive meningitis-arteritis.

Authors:  Arianna Maiolini; Meike Otten; Marion Hewicker-Trautwein; Regina Carlson; Andrea Tipold
Journal:  BMC Vet Res       Date:  2013-02-04       Impact factor: 2.741

8.  CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease.

Authors:  Yu Lun; Nozha Borjini; Noriko N Miura; Naohito Ohno; Nora G Singer; Feng Lin
Journal:  J Immunol       Date:  2021-06-07       Impact factor: 5.426

9.  Serum IP-10 and IL-17 from Kawasaki disease patients induce calcification-related genes and proteins in human coronary artery smooth muscle cells in vitro.

Authors:  Shun-Fu Chang; Shih-Feng Liu; Cheng-Nan Chen; Ho-Chang Kuo
Journal:  Cell Biosci       Date:  2020-03-11       Impact factor: 7.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.